Wells Fargo initiated coverage of Keros Therapeutics with an Overweight rating and $60 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KROS:
